NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
← Vendors

Shandong Aishi Biotechnology

china91 tests7 peptideslatest 5 Nov 2026
Peptide testing

Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply
+2 more ↓
68%
Finnrick rating
#348 of 500 ranked vendors
72 of 91 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Shandong Aishi Biotechnology's purity-focus record is broad but uneven, with GHK-Cu and Ipamorelin testing strongest while Tirzepatide and Retatrutide show recent purity setbacks. Tesamorelin and HGH sit at the weak end; recent testing is abundant, but batch-ID gaps and fill swings keep the catalog dispersed.

methodology →
vendor intelligence report
Vendor Intelligence Report: Shandong Aishi Biotechnology

Corporate records tie Aishi to a real Dezhou entity, but registry data and storefront claims conflict over staff, licences and factory capacity. The report maps a dead canonical domain, replacement sales funnels, shared COAs and a near-name buyer-confusion risk.

32 pages8 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.07
94%
16
2
Tirzepatide
$0.43
78%
32
3
Retatrutide
$0.93
76%
26
4
Ipamorelin
$1.96
74%
4
5
BPC-157
-
56%
3
6
Tesamorelin
$2.10
47%
7
7
HGH
-
38%
3
8
Cagrilintide
$4.40
-
0
9
MOTS-c
-
-
0
10
Semaglutide
$0.65
-
0
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%1 Mar 2026: 68%3 Mar 2026: 68%6 Mar 2026: 69%6 Mar 2026: 69%6 Mar 2026: 69%6 Mar 2026: 69%6 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 71%30 Apr 2026: 71%6 May 2026: 71%6 May 2026: 71%8 May 2026: 72%27 May 2026: 72%2 Jun 2026: 73%2 Jun 2026: 73%2 Jun 2026: 73%5 Jun 2026: 73%15 Jun 2026: 68%16 Jun 2026: 68%16 Jun 2026: 68%17 Jun 2026: 68%17 Jun 2026: 69%17 Jun 2026: 68%17 Jun 2026: 68%26 Jun 2026: 68%3 Aug 2026: 69%3 Aug 2026: 69%26 Aug 2026: 69%9 Sep 2026: 69%14 Sep 2026: 69%23 Sep 2026: 69%23 Sep 2026: 69%24 Sep 2026: 69%5 Oct 2026: 69%5 Oct 2026: 68%23 Oct 2026: 68%5 Nov 2026: 68%17 Nov 2026: current 68%68%73%68%Mar 26Nov 26
Peptide testing

Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply
Shandong Aishi Biotechnology test history
COA-backed lab tests
1-10 of 91

About Shandong Aishi Biotechnology test results from Finnrick

Shandong Aishi Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 91 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Shandong Aishi Biotechnology peptides in this dataset are BPC-157 (3 tests), GHK-Cu (16 tests) and HGH (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 91 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.

Test my supply